Nanotechnology-based solutions may be employed for diagnostics of SARS-CoV-2 infection and for treatment of COVID-19.

There are multiple pathogenetic targets for treatment of SARS-CoV-2 infection.

Why are most of the novel specific therapies limited to hospitalised patients?

What groups are at risk for severe COVID-19?

What are the advantages associated with the use of nanomaterials in the diagnosis and treatment of SARS-CoV-2 infection?

Leave a Reply